WO2015073444A1
|
|
Methods and compositions for modulating serotonin levels
|
US2015154379A1
|
|
Method and system to facilitate care of a patient during transport
|
EP2750702A1
|
|
Engineered sequences to facilitate expression of antigens in neisseria and methods of use
|
WO2012174278A1
|
|
Ultra-small apob-containing particles and methods of use thereof
|
EP2702400A2
|
|
Compositions and methods to assess the capacity of hdl to support reverse cholesterol transport
|
EP2613636A1
|
|
Dietary supplement and methods of use thereof
|
EP2496597A2
|
|
T-cell stimulating protein b and methods of use
|
CN102711814A
|
|
Chimeric factor h binding proteins (FHBP) and methods of use
|
CN102256619A
|
|
Ex-vivo passive protection bacteremia assay
|
WO2010048343A2
|
|
System and method for accepting and processing a facsimile image
|
WO2009158678A1
|
|
Lipophilic nucleic acid delivery vehicle and methods of use therefor
|
WO2009126808A2
|
|
Transgenic animal model of cancer and methods of use
|
WO2009076598A1
|
|
Use of unsaturated sphingosine compounds as chemotherapeutic agents for the treatment of cancer
|
EP2185576A1
|
|
Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
|
US2009022736A1
|
|
Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use
|
US2008248032A1
|
|
Compositions and methods for protection against cardiac and/or central nervous system tissue injury by inhibiting sphingosine-1-phosphate lyase
|
US2008166721A1
|
|
Methods and compositions for determining predisposition to inflammation-mediated cardiovascular disease
|
KR20080091777A
|
|
De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
|
US2008213787A1
|
|
Methods and compositions for KIR genotyping
|
WO2007027954A2
|
|
Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof
|